文献速递血栓与止血

对出血和血栓患者中检测到的血栓调节蛋白基因变异进行功能评估

Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.
PubMed 文献 · Blood · 2025-01-01

研究用多基因panel诊断601例遗传性出血或血栓性疾病患者,鉴定出6例血栓表型和2例出血表型的8个THBD变异,均为意义未明变异。通过重组可溶性和膜结合血栓调节蛋白功能实验,发现L433P完全抑制蛋白C和TAFI活化并显著降低凝血酶生成抑制,C175S可溶性形式作用减弱,其余变异未见功能影响。

要点

  • L433P血栓调节蛋白完全抑制蛋白C和TAFI活化,并显著降低对凝血酶生成的抑制。
  • 可溶性C175S血栓调节蛋白对凝血酶生成抑制和蛋白C活化减弱,膜结合形式未见影响。
  • 其余6个THBD变异未观察到对凝血酶生成、蛋白C或TAFI活化的影响。

核心结论

  • L433P血栓调节蛋白和潜在的C175S血栓调节蛋白的功能效应与血栓风险增加相容。
  • THBD变异罕见但可能与出血和血栓均相关,功能实验对理解其作用至关重要。

研究设计与样本

  • 使用多基因panel诊断601例遗传性出血或血栓性疾病患者。
  • 在Expi293F细胞中生产可溶性和细胞膜结合的重组血栓调节蛋白进行功能评估。

主要发现

  • 在6例血栓表型患者中鉴定出C175S、A282P、L433P、P501L、G502R和P508L变异,在2例出血表型患者中鉴定出P260A和T478I变异,均为意义未明变异。
  • L433P血栓调节蛋白对凝血酶生成抑制显著降低,并完全抑制蛋白C和凝血酶激活的纤溶抑制剂(TAFI)活化。
  • 可溶性C175S血栓调节蛋白对凝血酶生成抑制和蛋白C活化降低,而细胞膜结合重组血栓调节蛋白未见效应。
  • 其余血栓调节蛋白变异未观察到对凝血酶生成、蛋白C或TAFI活化的影响。
  • 表面等离子共振分析显示L433P存在时无凝血酶-血栓调节蛋白结合,因该残基位于相互作用位点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombomodulin (TM) expressed on endothelial cells regulates coagulation. Specific nonsense variants in the TM gene, THBD, result in high soluble TM levels causing rare bleeding disorders. In contrast, although THBD variants have been associated with venous thromboembolism, this association remains controversial. A multigene panel was used to diagnose 601 patients with inherited bleeding or thrombotic disorders. This resulted in the identification of 8 THBD variants for 6 patients with a thrombotic (C175S, A282P, L433P, P501L, G502R, and P508L) and 2 patients with a bleeding (P260A and T478I) phenotype. These were all classified as variants of uncertain significance, and we here aimed to assess their functional role in coagulation. For this purpose, soluble and cell membrane-bound recombinant TM were produced in Expi293F cells. L433P TM showed a marked decrease in the inhibition of thrombin generation and complete inhibition of protein C and thrombin activatable fibrinolysis inhibitor (TAFI) activation. Soluble C175S TM showed decreased inhibition of thrombin generation and protein C activation, whereas no effect was observed for cell membrane-bound recombinant TM. For the other TM variants, no effect on thrombin generation, protein C, or TAFI activation could be observed. Surface plasmon resonance analysis showed no thrombin-TM binding in the presence of L433P because this residue is located at their interaction site. In conclusion, our study shows the functional effects of L433P TM and potentially C175S TM, which are compatible with an increased thrombosis risk. THBD variants are rare but can be relevant to both bleeding and thrombosis. Functional assays for these variants are critical to understand their roles.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Van Laer C, Lavend'homme R, Baert S, et al. Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis. Blood. 2025. PMID: 39841007. doi:10.1182/blood.2024026454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。